Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 7/20 | 0.55 |
| ▸ | HTR2C | P28335 | 7/20 | 0.55 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.33 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25310969 | 0.84 | HTR2C (0.49) | HTR2AHTR2CP2RX7NPY5RHTT | |
| SCHEMBL25309043 | 0.84 | HTR2C (0.49) | HTR2AHTR2CP2RX7NPY5RHTT | |
| SCHEMBL27358260 | 0.79 | HTT (0.39) | HTR2AHTR2CHTTHDAC1HDAC6 | |
| SCHEMBL5428812 | 0.78 | HTT (0.60) | HTR2AHTR2CCYP1A2CYP3A4HTT | |
| SCHEMBL8647472 | 0.74 | CYP19A1 (0.35) | HTR2CCYP1A2CYP2C9HTR2BHTT | |
| SCHEMBL25309823 | 0.73 | HTR2A (0.64) | HTR2AHTR2CP2RX7CYP1A2CYP3A4 | |
| SCHEMBL31561791 | 0.73 | HTR2A (0.64) | HTR2AHTR2CP2RX7CYP1A2CYP3A4 | |
| SCHEMBL24669584 | 0.72 | EPHX2 (0.37) | HTTHDAC6MTNR1AMTNR1B | |
| SCHEMBL30515265 | 0.72 | HTR2A (0.63) | HTR2AHTR2CP2RX7CYP1A2CYP3A4 | |
| SCHEMBL25310206 | 0.72 | HTR2A (0.63) | HTR2AHTR2CP2RX7CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136548-A1 | FUNCTIONALIZED ALKYLAMINES | TERRAN BIOSCIENCES INC (US) | 2025-05-01 | — | — | US | disclosed |
| WO-2023141595-A2 | FUNCTIONALIZED ALKYLAMINES | TERRAN BIOSCIENCES, INC. (US) | 2023-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136548-A1 | FUNCTIONALIZED ALKYLAMINES | BDNF, HTR2A, NTRK2 | HTR2A 2/4885HTR2C 6/4885P2RX7 274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.